All Categories Archives - Page 262 of 264

Dysregulated Smooth Muscle Cell BMPR2–ARRB2 Axis Causes Pulmonary Hypertension

Lingli Wang, Jan Renier Moonen, Aigin Cao, Sarasa Isobe, Caiyun G. Li, Nancy F. Tojais, Shalina Taylor, David P. Marciano, Pi-I. Chen, Mingxia Xu, Dan Li, Rebecca L. Harper, Nesrine El-Bizri, YuMee Kim, Kryn Stankunas, Marlene RabinovitchStanford University School of Medicine, Howard Hughes Medical Institute, and Lucille Packard Children’s HospitalUnited States Circulation ResearchCirc Res 2023;

Dysregulated Smooth Muscle Cell BMPR2–ARRB2 Axis Causes Pulmonary Hypertension Read More »

Primary pulmonary vein stenosis during infancy: state of the art review

David B. Frank, Philip T. Levy, Corey A. Stiver, Brian A. Boe, Christopher W. Baird, Ryan M. Callahan, Charles V. Smith, Rachel D. Vanderlaan, Carl H. BackesUniversity of Pennsylvania and Children’s Hospital of Philadelphia. Harvard University and Boston Children’s Hospital. Ohio State University and Nationwide Children’s Hospital. University of Washington and Seattle Children’s Research Institute.

Primary pulmonary vein stenosis during infancy: state of the art review Read More »

Pulmonary hypertension in extremely preterm infants: a call to standardize echocardiographic screening and follow-up policy

Sanne Arjaans, Elvira A. H. Zwart, Marc Roofthooft, Elisabeth M. W. Kooi, Arend F. Bos, Rolf M. F. BergerBeatrix Children’s Hospital, University Medical Center Groningen and University of GroningenNetherlands European Journal of PediatricsEur J Pediatr 2021; 180: 1855-1865DOI: 10.1007/s00431-021-03931-5 AbstractPulmonary hypertension (PH) is a frequent complication in extremely preterm born infants that seriously affects outcome. We

Pulmonary hypertension in extremely preterm infants: a call to standardize echocardiographic screening and follow-up policy Read More »

Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review

Chantal Lokhorst, Sjoukje van der Werf, Rolf M. F. Berger, Johannes M. DouwesUniversity of Groningen, Beatrix Children’s Hospital and University Medical Center GroningenNetherlands Frontiers in Cardiovascular MedicineFront Cardiovasc Med 2022; 9: 1035453DOI: 10.3389/fcvm.2022.1035453 AbstractIntroduction: Currently, risk stratification is the cornerstone of determining treatment strategy for patients with pulmonary arterial hypertension (PAH). Since the 2015 European Society of

Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review Read More »

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management

Erika B. Rosenzweig, Steven H. Abman, Ian Adatia, Maurice Beghetti, Damien Bonnet, Sheila Haworth, D. Dunbar Ivy, Rolf M. F. BergerColumbia University and New York Presbyterian Hospital. University of Colorado and Children’s Hospital Colorado. Glenwood Children’s Heart Clinic. University Hospitals of Geneva and Lausanne. Hôpital Necker Enfants Malades, AP-HP, Université Paris Descartes. University College London.

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management Read More »

Correlation between Pulmonary Artery Pressure and Vortex Duration Determined by 4D Flow MRI in Main Pulmonary Artery in Patients with Suspicion of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Jean-Francois Deux, Lindsey A. Crowe, Leon Genecand, Anne-Lise Hachulla, Carl G. Glessgen, Stephane Noble, Maurice Beghetti, Jin Ning, Daniel Giese, Frederic Lador, Jean-Paul ValleeGeneva University Hospital. University of Geneva. Centre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pédiatrique. Siemens Medical Solutions. Siemens Healthcare GmbHSwitzerland, United States and Germany Journal of Clinical MedicineJ Clin Med 2022;

Correlation between Pulmonary Artery Pressure and Vortex Duration Determined by 4D Flow MRI in Main Pulmonary Artery in Patients with Suspicion of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Read More »

Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data

Malek Okour, Mita M. Thapar, Colm Farrell, Mary Ann Lukas, Maurice Beghetti, Misba BeeraheeGlaxo Smith Kline. ICON Clinical Research. University of Geneva and Centre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pédiatrique.United States, United Kingdom and Switzerland Journal of Clinical PharmacologyJ Clin Pharmacol 2022; DOI: 10.1002/jcph.2199 AbstractThis study aimed to develop a population pharmacokinetic (PK) model

Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data Read More »

International practice heterogeneity in pre-transplant management of pulmonary hypertension related to pediatric left heart disease

Rachel K. Hopper, Oscar van der Have, Seth A. Hollander, Anne I. Dipchand, Valeria Perez de Sa, Jeffery A. Feinstein, Karin Tran-LundmarkStanford University and Lucille Packard Children’s Hospital. Lund University. Skane University Hospital. University of Toronto and the Hospital for Sick ChildrenUnited States, Sweden and Canada Pediatric TransplantationPediatr Transplant 2023; DOI: 10.1111/petr.14461 AbstractBackground: Elevated pulmonary vascular resistance

International practice heterogeneity in pre-transplant management of pulmonary hypertension related to pediatric left heart disease Read More »